RT Book, Section
A1 Gonzalez, Ricardo J.
A1 Gronchi, Alessandro
A1 Pollock, Raphael E.
A2 Brunicardi, F. Charles
A2 Andersen, Dana K.
A2 Billiar, Timothy R.
A2 Dunn, David L.
A2 Kao, Lillian S.
A2 Hunter, John G.
A2 Matthews, Jeffrey B.
A2 Pollock, Raphael E.
SR Print(0)
ID 1164313374
T1 Soft Tissue Sarcomas
T2 Schwartz's Principles of Surgery, 11e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9781259835353
LK accessmedicine.mhmedical.com/content.aspx?aid=1164313374
RD 2024/04/19
AB Key  Points  Sarcomas  are  a  heterogeneous  group  of  tumors  that  can  occur  throughout  the  body  and  encompass  more  than  50  subtypes  with  distinct  histologic  lines  of  differentiation.  Approximately  two-thirds  of  soft  tissue  sarcomas  arise  in  the  extremities;  the  remaining  one-third  is  distributed  between  the  retroperitoneum,  trunk,  abdomen,  head,  and  neck.  Multimodality  treatment,  including  surgical  resection,  radiation  therapy,  and,  in  selected  cases,  systemic  chemotherapy,  has  been  applied  to  patients  with  locally  advanced,  high-grade,  extremity  sarcomas.  Overall  5-year  survival  rate  for  patients  with  all  stages  of  soft  tissue  sarcoma  is  50%  to  60%.  These  rare  tumors  account  for  less  than  1%  of  cancer  in  adults  (estimated  10,000  cases  per  year  in  the  United  States)  and  represent  15%  of  cancers  in  children.  The  treatment  algorithm  for  soft  tissue  sarcomas  depends  on  tumor  stage,  site,  and  histology.  Of  the  patients  who  die  of  sarcoma,  most  will  succumb  to  metastatic  disease  in  the  lungs,  which  80%  of  the  time  occurs  within  2  to  3  years  of  the  initial  diagnosis.  Progress  in  the  understanding  of  soft  tissue  sarcoma  biology  is  crucial  for  the  development  of  new  treatments.